Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Insulin (ORMD-0801) for NASH in T2DM Patients
NCT04618744Phase 2Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of ORMD-0801 in Nonalcoholic steatohepatitis (NASH), sponsored by Oramed Pharmaceuticals Inc.. Started Nov 2020; status: completed.
02
Drugs
ORMD-0801
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04618744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618744.